Stockreport

Xynomic Dosed First Patient in Phase 1/2 Lymphoma Trial

 (XYN) 
PDF RALEIGH, N.C. and SHANGHAI, June 06, 2019 (GLOBE NEWSWIRE) --  Xynomic Pharmaceuticals Holdings, Inc. (“Xynomic”, Nasdaq: XYN), a clinical stage US-China oncology drug [Read more]